Phase 2 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have cystic fibrosis with a long-term lung infection caused by a bacteria called Pseudomonas aeruginosa, who are either taking inhaled antibiotics as part of their usual care or not taking inhaled antibiotics at all
- People aged 18 or older
- People whose lung function test result (called FEV1) falls between 40% and 80% of the expected value for their age and size
- People whose lung disease is considered stable at the time of joining
- People who are able to provide sputum (mucus coughed up from the lungs) samples at scheduled visits, whether coughed up naturally, collected at home, or collected at a clinic
Who may not be able to join:
- People who have a known allergy or sensitivity to bacteriophages (viruses that target bacteria) or to any ingredients in the study treatment
- People who have received bacteriophage therapy in the 6 months before the screening visit or before the first study day
- People in whom a specific harmful bacteria called Burkholderia cenocepacia has been detected in their airways within the past year, or at the time of screening
- People currently receiving systemic (whole-body) treatment for a condition called allergic bronchopulmonary aspergillosis, which is a lung reaction to a type of fungus
- People currently being treated for an active infection with non-tuberculous mycobacteria, or in whom a specific bacteria called Mycobacterium abscessus was detected in the 12 months before screening
- People with a history of severely low white blood cell counts (a condition called severe neutropenia)
- People who have had a lung transplant
- People who have had any other solid organ transplant (such as a kidney or liver)
- People with a condition that weakens the immune system, whether present from birth or developed over time
- People who started or changed a type of cystic fibrosis medication called a CFTR modulator less than 3 months before the screening visit
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Urania Rappo, MD, BiomX, Inc.
Phone: 1-617-256-2625
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in sputum Pseudomonas aeruginosa (PsA) burden at 8 weeks (EOT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.